drugset / Trial / NCT01387087

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K

NCT01387087

Phase 1 Completed 72 enrolled Astellas Pharma Inc
RandomizedSingle-groupQuadruple-blind

Summary

The objective of the study is to explore safety and tolerability of single ascending doses of ASP015K, establish the maximum tolerated dose, and determine the pharmacokinetics and pharmacodynamics in healthy volunteers.

Timeline

Start
2008-07
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject peficitinib Small molecule Oral

Indications

No indication recorded.